Exchange: NASDAQ·Updated 06:34 PM EDT
EXOZ logo

EXOZ eXoZymes Inc.

$6.44
$0.245
(3.96%)
Today
Closed $6.44
$0.005
(0.08%)
After Hours
Mkt Cap$59.73M
Vol16,336.00

About EXOZ

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
46

Neutral Sentiment

How do you feel about EXOZ?

OnlyFibs
$EXOZ | Fundamental & Technical Breakdown 📊🧪 • Business Overview: Development-stage synthetic biology company focused on enzymatic platforms for scalable biological molecule discovery. • Profitability & Financials: Unprofitable. Early-stage micro-cap company with no active commercial revenue, operating with net losses (~-$1.20 EPS). • Latest Earnings Report: Missed/Unprofitable (Reported EPS of -$0.33 with zero revenue). • Wall Street Analyst Consensus: Unrated / Low Coverage. Limited institutional analyst coverage given small market cap (~$57M). • Overall Bias: Cautiously Speculative / Bottoming Watch (Technicals compressing in a falling wedge near $6.10 support; breakout triggers above $7.50). Key Levels for Bulls & Bears: • Bull Reclaim Trigger: $7.50 / $8.20 • Overhead Targets: $9.10 / $10.15 • Critical Support Pivot: $6.10 • Bearish Invalidation Level: $5.90 / $4.35 #EXOZ #biotech #smallcaps #fundamentalanalysis #hovdid
focafoca99
$EXOZ hosted its Q2 2026 results webcast and highlighted a $6M public offering and a $2M NIH grant.

Advertisement|Remove ads.